47
Participants
Start Date
August 31, 2003
Primary Completion Date
September 30, 2009
Study Completion Date
February 28, 2011
lestaurtinib
Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
Morgan Stanley Children's Hospital of New York-Presbyterian, New York
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Chicago Comer Children's Hospital, Chicago
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Lucille Salter Packer Children's Hospital, Stanford University, Palo Alto
Children's Hospital and Regional Medical Center - Seattle, Seattle
Childrens Hospital Los Angeles, Los Angeles
Children's Hospital Boston, Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Philadelphia, Philadelphia
Hospital for Sick Children, Toronto
National Cancer Institute (NCI)
NIH
New Approaches to Neuroblastoma Therapy Consortium
OTHER